[go: up one dir, main page]

TNSN95004A1 - Derives tetracycliques, procedes de preparation et emploi - Google Patents

Derives tetracycliques, procedes de preparation et emploi

Info

Publication number
TNSN95004A1
TNSN95004A1 TNTNSN95004A TNSN95004A TNSN95004A1 TN SN95004 A1 TNSN95004 A1 TN SN95004A1 TN TNSN95004 A TNTNSN95004 A TN TNSN95004A TN SN95004 A TNSN95004 A TN SN95004A TN SN95004 A1 TNSN95004 A1 TN SN95004A1
Authority
TN
Tunisia
Prior art keywords
6alkyle
3alkyle
members
compound
formula
Prior art date
Application number
TNTNSN95004A
Other languages
English (en)
Inventor
Claude-Marie Daugan Alain
Original Assignee
Glaxo Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10749089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN95004(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Lab Sa filed Critical Glaxo Lab Sa
Publication of TNSN95004A1 publication Critical patent/TNSN95004A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN COMPOSE DE FORMULE (I) ET LES SELS ET SOLVANTS DE CELUI-CI, OU: R0 REPRESENTE HYDROGENE, HALOGENE OU C1-6ALKYLE ; R1 REPRESENTE HYDROGENE, C1-6ALKYLE, C2-6ALKENYLE, C2-6ALKYNYLE, HALO C1-6ALKYLE, C3-8CYCLOALKYLE, C3-8CYCLOALKYL-C1-3ALKYLE, ARYL C1-3ALKYLE OU HETEROARYL C1-3ALKYLE ; R2 REPRESENTE UN NOYAU AROMATIQUE MONOCYCLIQUE OPTIONNELLEMENT SUBSTITUE SELECTIONNE A PARTIR DE BENZENE, THIOPHENE, FURANE ET PYRIDINE OU UN NOYAU BICYCLIQUE OPTIONNELLEMENT SUBSTITUE FIXE AU RESTE DE LA MOLECULE PAR L'UN DES ATOMES DE CARBONE DU NOYAU BENZENE ET OU LE NOYAU SOUDE A EST UN NOYAU A 5 OU 6 MEMBRES QUI PEUT ETRE SATURE OU PARTIELLEMENT OU ENTIEREMENT INSATURE ET CONTIENT DES ATOMES DE CARBONES ET OPTIONNELLEMENT UN OU DEUX HETEROATOME SELECTIONNES A PARTIR D'OXYGENE, SOUFRE ET AZOTE ; ET R3 REPRESENTE HYDROGENE OU C1-3ALKYLE, OU R1 ET R3 ENSEMBLE REPRESENTENT UNE CHAINE ALKYLE OU ALKENYLE A 3 OU 4 MEMBRES. UN COMPOSE DE FORMULE (I) EST UN INHIBITEUR PUISSANT ET SELECTIF DE LA PHOSPHODIESTERASE SPECIFIQUE DU GUANOSINE 3'5'- MONOPHOSPHATE CYCLIQUE (PDE CGMP SPECIFIQUE) ET PRESENTE UNE UTILITE DANS DE NOMBREUX DOMAINES THERAPEUTIQUE OU CETTE INHIBITION EST JUGEE UTILE, NOTAMMENT FACE AUX AFFECTIONS CARDIOVASCULAIRES.
TNTNSN95004A 1994-01-21 1995-01-20 Derives tetracycliques, procedes de preparation et emploi TNSN95004A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9401090A GB9401090D0 (en) 1994-01-21 1994-01-21 Chemical compounds

Publications (1)

Publication Number Publication Date
TNSN95004A1 true TNSN95004A1 (fr) 1996-02-06

Family

ID=10749089

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN95004A TNSN95004A1 (fr) 1994-01-21 1995-01-20 Derives tetracycliques, procedes de preparation et emploi

Country Status (48)

Country Link
US (5) US5859006A (fr)
EP (1) EP0740668B1 (fr)
JP (3) JP3808095B2 (fr)
KR (1) KR100357411B1 (fr)
CN (2) CN1045777C (fr)
AP (1) AP556A (fr)
AT (1) ATE169018T1 (fr)
AU (2) AU689205B2 (fr)
BG (1) BG62733B1 (fr)
BR (1) BR9506559C8 (fr)
CA (1) CA2181377C (fr)
CO (1) CO4340684A1 (fr)
CZ (1) CZ286566B6 (fr)
DE (2) DE10399006I2 (fr)
DK (1) DK0740668T3 (fr)
EE (1) EE03231B1 (fr)
EG (1) EG25852A (fr)
ES (1) ES2122543T3 (fr)
FI (1) FI113176B (fr)
GB (1) GB9401090D0 (fr)
HR (1) HRP950023B1 (fr)
HU (1) HU222494B1 (fr)
IL (1) IL112384A (fr)
IN (1) IN183942B (fr)
IS (1) IS1888B (fr)
LU (1) LU91017I2 (fr)
LV (1) LV11690B (fr)
MA (1) MA23433A1 (fr)
MX (1) MX9602904A (fr)
MY (1) MY114663A (fr)
NL (1) NL300124I2 (fr)
NO (2) NO306465B1 (fr)
NZ (1) NZ279199A (fr)
OA (1) OA10584A (fr)
PE (1) PE49495A1 (fr)
PL (1) PL179744B1 (fr)
RO (1) RO117794B1 (fr)
RU (1) RU2142463C1 (fr)
SA (1) SA95150475B1 (fr)
SG (1) SG49184A1 (fr)
SI (1) SI0740668T1 (fr)
SK (1) SK280879B6 (fr)
SV (1) SV1995000002A (fr)
TN (1) TNSN95004A1 (fr)
TW (1) TW378210B (fr)
UY (1) UY23893A1 (fr)
WO (1) WO1995019978A1 (fr)
ZA (1) ZA95424B (fr)

Families Citing this family (219)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
US6046216A (en) 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US5874440A (en) 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6060477A (en) 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
CZ358598A3 (cs) 1996-05-10 1999-03-17 Icos Corporation Karbolinové deriváty
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US6071934A (en) 1997-03-25 2000-06-06 Cell Pathways, Inc. Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
AU756136B2 (en) 1997-06-23 2003-01-02 Queen's University At Kingston Microdose therapy
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
IL132406A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
US6133271A (en) 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6211220B1 (en) 1998-11-23 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives
US6348032B1 (en) 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
US6420410B1 (en) 1998-11-24 2002-07-16 Cell Pathways, Inc. Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6211177B1 (en) 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
US6358992B1 (en) 1998-11-25 2002-03-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with indole derivatives
CA2367138C (fr) 1999-03-24 2010-10-05 Alejandro M. S. Mayer Utilisation de manzamines en tant qu'anti-inflammatoires
MXPA00003997A (es) * 1999-04-30 2002-03-08 Lilly Icos Llc Articulos de fabricacion.
US6451807B1 (en) 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
US6943166B1 (en) * 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
WO2001008686A1 (fr) * 1999-08-03 2001-02-08 Lilly Icos Llc Compositions pharmaceutiques a base de beta-carboline
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
JP2003511452A (ja) 1999-10-11 2003-03-25 ファイザー・インク ホスホジエステラーゼ阻害剤としての５−（２−置換−５−ヘテロシクリルスルホニルピリド−３−イル）−ジヒドロピラゾロ［４，３−ｄ］ピリミジン−７−オン
TW200400821A (en) * 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
US6562830B1 (en) 1999-11-09 2003-05-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives
US6376489B1 (en) * 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
AU2001255849B8 (en) 2000-04-19 2006-04-27 Lilly Icos, Llc. PDE-V inhibitors for treatment of Parkinson's Disease
UA74826C2 (en) 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
UA72611C2 (uk) * 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
CA2411008C (fr) 2000-06-07 2006-04-11 Lilly Icos Llc Derives de 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4b]indole-1,4-dione
AU2001263278A1 (en) 2000-06-23 2002-01-08 Lilly Icos Llc Cyclic gmp-specific phosphodiesterase inhibitors
JP4169149B2 (ja) * 2000-06-23 2008-10-22 リリー アイコス リミテッド ライアビリティ カンパニー 化学的化合物
CA2413510C (fr) * 2000-06-26 2007-12-11 Lilly Icos Llc Composes chimiques
MXPA03000688A (es) * 2000-07-24 2004-11-01 Bayer Cropscience Ag Bifenilcarboxiamidas.
US7034027B2 (en) * 2000-08-02 2006-04-25 Lilly Icos Llc Fused heterocyclic derivatives as phosphodiesterase inhibitors
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
AU2001292698A1 (en) * 2000-10-02 2002-04-15 Lilly Icos Llc Hexahydropyrazino `1'2' : 1, 6!- pyrido `3, 4-b! indole-1, 4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction
CA2423308A1 (fr) 2000-10-02 2002-04-11 Lilly Icos Llc Composes chimiques
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
EP1211313A3 (fr) * 2000-11-01 2003-04-23 Pfizer Limited Modulation de l'activité PDE11A activity
US6828473B2 (en) 2000-11-01 2004-12-07 Pfizer Inc. Modulation of PDE11A activity
ES2271080T3 (es) * 2000-11-06 2007-04-16 Lilly Icos Llc Derivados de indol como inhibidores de pde5.
US7115621B2 (en) * 2001-04-25 2006-10-03 Lilly Icos Llc Chemical compounds
FR2824829B1 (fr) * 2001-05-16 2005-06-03 Macef Nouveaux derives de dihydroimidazo [5,1-a]-beta-carboline, leur procede de preparation et leur application a titre de medicament
US6992192B2 (en) 2001-06-05 2006-01-31 Lilly Icos Llc. Carboline derivatives as PDE5 inhibitors
MXPA03011080A (es) * 2001-06-05 2004-07-08 Lilly Icos Llc Compuestos tetraciclicos como inhibidores de pde5.
US7098209B2 (en) 2001-06-05 2006-08-29 Lilly Icos Llc Pyrazino [1'2':1,6 ] pyrido [3, 4-b] indole-1,4-dione derivatives
ATE335742T1 (de) * 2001-06-21 2006-09-15 Lilly Icos Llc Carbolinderivate als pdev inhibitoren
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US6943171B2 (en) * 2001-11-09 2005-09-13 Schering Corporation Polycyclic guanine derivative phosphodiesterase V inhibitors
ATE368040T1 (de) * 2001-11-14 2007-08-15 Ortho Mcneil Pharmaceutical Co Substituierte tetrazyklische pyprolochinolonderivate als phosphodiesterase- inhibitoren
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
JP2005529927A (ja) * 2002-05-23 2005-10-06 ファイザー インコーポレイテッド 新規な組み合わせ
EP1719772A1 (fr) 2002-05-31 2006-11-08 Schering Corporation Procédé de préparation d'inhibiteurs de la phosphodiesterase v de la xanthine et leur précurseurs
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
CN100430395C (zh) * 2002-07-31 2008-11-05 利利艾科斯有限公司 改进的皮克特-施彭格勒反应和由该反应制备得到的产物
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
PL377657A1 (pl) 2002-12-13 2006-02-06 Warner-Lambert Company Llc Ligand Ó-2-Ű do leczenia dolegliwości dolnych dróg moczowych
BRPI0409229A (pt) 2003-04-01 2006-03-28 Applied Research Systems inibidores das fosfodiesterases na infertilidade
DK1620437T3 (da) 2003-04-29 2009-08-24 Pfizer Ltd 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
BRPI0410326A (pt) 2003-05-22 2006-05-23 Altana Pharma Ag composição compreendendo um inibidor pde4 e inibidor pde5
DK1644021T3 (da) 2003-06-13 2012-10-29 Ironwood Pharmaceuticals Inc Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
EP1637521B1 (fr) 2003-06-23 2013-06-19 Ono Pharmaceutical Co., Ltd. Nouveau compose heterocyclique tricyclique
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
EP1699436A2 (fr) * 2003-12-12 2006-09-13 Myogen, Inc. Preparations a base d'enoximone et leur utilisation pour traiter l'hypertrophie cardiaque et l'insuffisance cardiaque
WO2005068464A2 (fr) * 2003-12-15 2005-07-28 Cadila Healthcare Limited Procede de preparation de tadalafil et ses intermediaires
BRPI0506994A (pt) 2004-01-22 2007-07-03 Pfizer derivados de triazol que inibem a atividade antagonista da vasopressina
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
WO2005092333A1 (fr) * 2004-03-22 2005-10-06 Myogen, Inc. (r)-enoximone sulfoxyde et son utilisation dans le traitement de maladies induites par pde-iii
JP2007530563A (ja) * 2004-03-22 2007-11-01 ミオゲン インコーポレイティッド （ｓ）−エノキシモンスルホキシドおよびｐｄｅ−ｉｉｉ媒介疾患の治療におけるその使用
US7569572B2 (en) 2004-04-07 2009-08-04 Pfizer Inc Pyrazolo[4,3-D]pyrimidines
WO2005116030A1 (fr) * 2004-05-31 2005-12-08 Matrix Laboratories Ltd Procede d'elaboration de tadalafil
WO2006007213A1 (fr) * 2004-06-23 2006-01-19 Myogen, Inc. Formulations d'enoximone et utilisation dans le traitement de maladies a mediation par pde-iii
AU2005277384B2 (en) 2004-08-17 2011-11-17 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
WO2006049986A1 (fr) * 2004-10-28 2006-05-11 Dr. Reddy's Laboratories Ltd. Formes polymorphiques du tadalafil
KR20070072891A (ko) * 2004-11-02 2007-07-06 테바 파마슈티컬 인더스트리즈 리미티드 타달라필 결정형 및 이의 제조 방법
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
EP1829874B1 (fr) 2004-12-22 2014-02-12 Ono Pharmaceutical Co., Ltd. Compose tricyclique et son utilisation
CA2596667A1 (fr) * 2005-02-25 2006-08-31 Teva Pharmaceutical Industries Ltd. Processus pour synthetiser le tadalafil
WO2006091974A1 (fr) * 2005-02-25 2006-08-31 Teva Pharmaceutical Industries Ltd. Tadalafil possedant des dimensions importantes des particules et procede de fabrication correspondant
EP1851223A1 (fr) * 2005-02-25 2007-11-07 Teva Pharmaceutical Industries Ltd Methode de purification de tadalafil
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
KR20070110941A (ko) * 2005-04-12 2007-11-20 테바 파마슈티컬 인더스트리즈 리미티드 타달라필 중간체의 제조 방법
AU2006237300B2 (en) 2005-04-19 2011-10-13 Takeda Gmbh Roflumilast for the treatment of pulmonary hypertension
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
BRPI0609225A2 (pt) 2005-05-12 2010-03-09 Pfizer formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas
US20070010525A1 (en) * 2005-06-27 2007-01-11 Meyer Jackson Method and compositions for modulating neuropeptide hormone secretion
JP2009502961A (ja) * 2005-07-29 2009-01-29 コンサート ファーマシューティカルズ インコーポレイテッド 新規な医薬組成物
US7863274B2 (en) * 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
EP1912650B8 (fr) 2005-08-03 2017-10-18 Sprout Pharmaceuticals, Inc. Utilisation de la flibansérine dans le traitement de l'obésité
CA2620333A1 (fr) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenese par modulation du recepteur muscarinique
EP2258357A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse avec inhibiteur de l'acetylcholinestérase
CA2622200A1 (fr) * 2005-09-13 2007-03-22 Elan Pharma International, Limited Formulations nanoparticulaires de tadalafil
CA2624788C (fr) 2005-10-12 2011-04-19 Unimed Pharmaceuticals, Llc Gel de testosterone ameliore et methode d'utilisation
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
EP1945214A1 (fr) 2005-10-29 2008-07-23 Boehringer Ingelheim International GmbH Derives de benzimidazolone utiles pour le traitement des troubles premenstruels et d'autres troubles sexuels chez la femme
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007100387A2 (fr) * 2005-11-03 2007-09-07 Dr. Reddy's Laboratories Ltd. Procédé de préparation de tadalafil
TWI435729B (zh) 2005-11-09 2014-05-01 Combinatorx Inc 治療病症之方法，組合物及套組
US7202229B1 (en) * 2005-12-30 2007-04-10 Alan James Group, Llc. Aspirin formulation for cardiovascular health
US7201929B1 (en) * 2005-12-30 2007-04-10 Alan James Group, Llc. Aspirin formulation for cardiovascular health
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP1991212A1 (fr) * 2006-03-08 2008-11-19 Braincells, Inc. Modulation de neurogenèse par des agents nootropes
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007110734A1 (fr) * 2006-03-24 2007-10-04 Glenmark Pharmaceuticals Limited Procede de preparation de tadalafil
US20080027072A1 (en) * 2006-04-20 2008-01-31 Ampla Pharmaceuticals, Inc. Potentiation of MC4 receptor activity
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
CA2651862A1 (fr) * 2006-05-09 2007-11-22 Braincells, Inc. Neurogenese induite par le recepteur 5ht
EP2382975A3 (fr) 2006-05-09 2012-02-29 Braincells, Inc. Neurogénèse par modulation d'angiotensine
US20090291958A1 (en) * 2006-06-08 2009-11-26 Auspex Pharmaceuticals, Inc. Substituted PDE5 inhibitors
JP2009541443A (ja) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
BRPI0621852A2 (pt) * 2006-07-07 2011-12-20 Teva Pharma compostos sólidos consistindo de tadalafil e pelo menos um veìculo
DK2046292T3 (da) 2006-07-21 2010-06-07 Novartis Ag Formuleringer for benzimidazolylpyridylethere
KR20090042967A (ko) 2006-08-14 2009-05-04 베링거 인겔하임 인터내셔날 게엠베하 플리반세린 제형 및 이의 제조방법
CN104721168A (zh) 2006-08-25 2015-06-24 贝林格尔·英格海姆国际有限公司 控制释放系统及其制造方法
AR062501A1 (es) * 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
JP2010502722A (ja) * 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2663347A1 (fr) * 2006-09-19 2008-03-27 Braincells, Inc. Modulation induite par ppar de la neurogenese
ES2544724T3 (es) 2006-12-12 2015-09-03 Gilead Sciences, Inc. Composición para tratar una hipertensión pulmonar
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
KR20130122023A (ko) 2007-02-12 2013-11-06 디엠아이 바이오사이언시스 인코포레이티드 트라마돌의 부작용을 감소시키는 방법
CA2677690C (fr) 2007-02-12 2012-05-15 James V. Winkler Traitement destine a une ejaculation precoce et aux troubles de l'erection comorbides
WO2008103470A2 (fr) * 2007-02-21 2008-08-28 Trustees Of Columbia University In The City Of New York Composés létaux dépendants du signal de ras oncogénique
US20090098211A1 (en) * 2007-04-25 2009-04-16 Ilan Zalit Solid dosage forms
FR2916200A1 (fr) * 2007-05-18 2008-11-21 Fourtillan Snc Nouveaux derives des 1,2,3,4,6,7,12,12a-octahydro pyrazino[1',2':1,6]pyrido[3,4-b]indoles, leur preparation et leur utilisation en therapeutique
DE102007028869A1 (de) * 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
PT2170880E (pt) 2007-06-29 2012-10-29 Ranbaxy Lab Ltd Processo para a preparação de intermediários de compostos tetracíclicos
EP2033962A1 (fr) * 2007-08-22 2009-03-11 4Sc Ag Dérivés tétracycliques d'indolopyridines comme inhibiteurs de EG5
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
WO2009091777A1 (fr) * 2008-01-15 2009-07-23 Forest Laboratories Holdings Limited Le nébivolol dans le traitement du dysfonctionnement sexuel
ITMI20080285A1 (it) * 2008-02-22 2009-08-23 Endura Spa Procedimento per la preparazione di esteri di acidi tetraidro-1h-betacarbolin-3-carbossilici
EP2107059A1 (fr) 2008-03-31 2009-10-07 LEK Pharmaceuticals D.D. Conversion de tryptophane en dérivés de ß-carboline
PL385356A1 (pl) 2008-06-03 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania tadalafilu
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
EP2181997A1 (fr) 2008-10-30 2010-05-05 Chemo Ibérica, S.A. Procédé de préparation de tadalafil
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
EP2379076B1 (fr) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Inhibiteurs de la phosphodiestérase et utilisations de ces derniers
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
WO2010099323A1 (fr) 2009-02-26 2010-09-02 Thar Pharmaceuticals, Inc. Cristallisation de composés pharmaceutiques
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
CN102970965A (zh) 2010-04-05 2013-03-13 Sk化学公司 含有pde5抑制剂的减少皮肤皱纹的合成物
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
ES2627944T3 (es) 2010-10-15 2017-08-01 Gilead Sciences, Inc. Composiciones y métodos de tratamiento de hipertensión pulmonar
JP5816704B2 (ja) 2011-02-10 2015-11-18 インテルキム、ソシエダッド アノニマ テトラヒドロ−β−カルボリンから誘導される化合物を得る方法
RU2013141446A (ru) 2011-02-10 2015-03-20 Синтон Бв Фармацевтическая композиция, содержащая тадалафил и циклодекстрин
WO2012107092A1 (fr) 2011-02-10 2012-08-16 Synthon Bv Composition pharmaceutique comportant du tadalafil et une cyclodextrine
WO2012107090A1 (fr) 2011-02-10 2012-08-16 Synthon Bv Composition de granulés comportant du tadalafil et un délitant
US20120123124A1 (en) * 2011-04-22 2012-05-17 Drug Process Licensing Associates, LLC Manufacturing process for Tadalafil from racemic or L-tryptophan
CN102180876B (zh) * 2011-05-28 2016-05-18 浙江华海药业股份有限公司 一种他达那非晶型i的制备方法
EP2535049A1 (fr) 2011-06-17 2012-12-19 Proyecto de Biomedicina Cima, S.L. Tadalafil pour le traitement de la démence
CN102367253B (zh) * 2011-09-20 2016-04-06 浙江华海药业股份有限公司 一种制备他达拉非晶型a的方法
WO2013067309A1 (fr) 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Procédés et compositions pour l'administration orale de composés agonistes d'un récepteur de la mélanocortine
EP2804603A1 (fr) 2012-01-10 2014-11-26 President and Fellows of Harvard College Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation
WO2013109738A1 (fr) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Nouveaux inhibiteurs de la phosphodiestérase et utilisations de ceux-ci
WO2013109227A1 (fr) 2012-01-18 2013-07-25 Mahmut Bilgic Compositions pharmaceutiques contenant du ceftibutène
WO2013109223A1 (fr) 2012-01-18 2013-07-25 Mahmut Bilgic Formulations de particules de tadalafil sous forme effervescente
WO2014092661A1 (fr) 2012-01-18 2014-06-19 Mahmut Bilgic Formulations particulaires de tadalafil sous forme effervescente
US10092651B2 (en) 2012-02-28 2018-10-09 Seoul Pharma Co., Ltd. High-content fast dissolving film with masking of bitter taste comprising sildenafil as active ingredient
EP2903619B1 (fr) 2012-10-05 2019-06-05 Robert I. Henkin Inhibiteurs de la phosphodiestérase destinés à traiter des troubles du goût et de l'odorat
ES2903151T3 (es) 2012-12-04 2022-03-31 Aribio Inc Composición que comprende inhibidor de fosfodiesterasa tipo 5 para inhibir la apoptosis de células nerviosas
KR101953735B1 (ko) 2012-12-14 2019-03-04 한미약품 주식회사 포스포다이에스터라제-5 억제제를 포함하는 츄정
ES2700989T3 (es) 2012-12-21 2019-02-20 Mayo Found Medical Education & Res Métodos y materiales para tratar estenosis de la válvula aórtica calcificada
HK1217488A1 (zh) 2013-02-21 2017-01-13 Adverio Pharma Gmbh {4,6-二氨基-2-[1-(2-氟苄基)-1h-吡唑并[3,4-b]吡啶-3-基]嘧啶-5-基}甲基氨基甲酸甲酯的形式
CN103232451A (zh) * 2013-05-14 2013-08-07 张家港威胜生物医药有限公司 一种他达那非的简易制备工艺
US10899756B2 (en) 2013-07-17 2021-01-26 The Trustees Of Columbia University In The City Of New York Phosphodiesterase inhibitors and uses thereof
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
WO2015126944A1 (fr) 2014-02-18 2015-08-27 Henkin Robert I Procédés et compositions permettant de diagnostiquer et de traiter une perte et/ou une distorsion du goût ou de l'odorat
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
US10300042B2 (en) 2014-06-23 2019-05-28 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
ES2784251T3 (es) 2014-06-30 2020-09-23 Montero Gida Sanayi Ve Ticaret As Formulaciones de disgregación por vía oral de tadalafilo
EP2962684A1 (fr) 2014-06-30 2016-01-06 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations de tadalafil se désintégrant par voie orale
CN104086546B (zh) * 2014-07-14 2016-08-17 福建广生堂药业股份有限公司 他达拉非的药用酸盐及其制备方法
EA035390B1 (ru) 2014-07-23 2020-06-05 КРКА, д.д., НОВО МЕСТО Совместный осадок тадалафила с фармацевтически приемлемыми эксципиентами, содержащая его фармацевтическая композиция и способ их получения
KR101645652B1 (ko) 2014-11-03 2016-08-08 (주)퓨젠바이오농업회사법인 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
KR102457316B1 (ko) * 2015-06-26 2022-10-20 총킹 디캉 에릴 파마 씨오. 엘티디. 새로운 5형포스포디에스테라아제 억제제 및 그 용도
CN105541840B (zh) * 2015-12-31 2017-12-05 湖南千金湘江药业股份有限公司 关键中间体及其合成方法和在制备他达拉非方面的应用
CN105541835B (zh) * 2015-12-31 2017-12-05 湖南千金湘江药业股份有限公司 顺式四氢咔啉中间体及其合成方法和在制备他达拉非方面的应用
CN110381951A (zh) 2016-12-14 2019-10-25 瑞必治公司 用于治疗肺性高血压和其他肺病症的方法及组合物
CN106977516B (zh) * 2017-03-02 2019-06-18 山东裕欣药业有限公司 一种他达拉非的制备方法
SG11202110533RA (en) 2019-04-10 2021-10-28 Mayo Found Medical Education & Res Methods and materials for gender-dependent treatment of cardiovascular dysfunction
RU2692764C1 (ru) 2019-04-26 2019-06-27 Общество с ограниченной ответственностью "Балтфарма" Способ получения тадалафила
CN111995658B (zh) * 2019-05-27 2022-08-02 首都医科大学 Ldv修饰的五环哌嗪二酮及其制备和应用
JP2022540866A (ja) 2019-07-15 2022-09-20 バイオラブ・サヌス・ファーマセウティカ・エルティーディーエー． ３－（ベンゾ［ｄ］［１，３］ジオキサゾール－５－イル）－７－（１－ヒドロキシプロパン－２－イル）－１－（１Ｈ－インドール－３－イル）－６，７－ジヒドロ－３Ｈ－オキサゾール［３，４－ａ］ピラジン－５，８－ジオン化合物の立体異性体およびその抗腫瘍剤およびホスホジエステラーゼ酵素阻害剤としての使用
CN110606847A (zh) * 2019-07-30 2019-12-24 中国医药集团总公司四川抗菌素工业研究所 一种他达拉非顺式中间体的制备方法及其应用
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
WO2021245192A1 (fr) 2020-06-04 2021-12-09 Topadur Pharma Ag Nouveaux activateurs de la guanylate cyclase soluble à double mode d'action et inhibiteurs de phosphodiestérase et leurs utilisations
EP4656194A1 (fr) 2023-01-25 2025-12-03 Aribio Co., Ltd Composition pour prévenir ou traiter un trouble de stress post-traumatique, comprenant un inhibiteur de phosphodiestérase de type 5 en tant que principe actif
AU2024220563A1 (en) 2023-02-16 2025-08-14 University Of Rochester Improving glymphatic-lymphatic efflux
CN116715667A (zh) * 2023-06-20 2023-09-08 常州制药厂有限公司 一种他达拉非新晶型b及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644384A (en) * 1969-06-09 1972-02-22 Sterling Drug Inc Certain 2-(alpha-haloacetyl) - 1 2 3 4-tetrahydro - 9h - pyrido(3 4-b)indole-3-carboxylates and derivatives
US3717638A (en) * 1971-03-11 1973-02-20 Sterling Drug Inc 1,2,3,4,6,7,12,12A-OCTAHYDRO-2-PHENYLPYRAZINO[2',1':6,1]PYRIDO[3,4-b]INDOLES AND INTERMEDIATES THEREFOR
US3917599A (en) * 1973-03-30 1975-11-04 Council Scient Ind Res 2-Substituted-1,2,3,4,6,7,12,12A-octahydropyrazino(2{40 ,1{40 :6,1)pyrido(3,4-B)indoles
GB1454171A (en) * 1973-10-19 1976-10-27 Council Scient Ind Res Tetracyclic compounds
US4273773A (en) * 1979-09-24 1981-06-16 American Home Products Corporation Antihypertensive tricyclic isoindole derivatives
EP0357122A3 (fr) * 1988-08-29 1991-10-23 Duphar International Research B.V L'application des bêta-carbolines, benzofurane et benzothiophène analogues pour obtenir un médicament à activité cytostatique
DE3830096A1 (de) * 1988-09-03 1990-03-15 Hoechst Ag Piperazindione mit psychotroper wirkung
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6225315B1 (en) * 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance

Also Published As

Publication number Publication date
ATE169018T1 (de) 1998-08-15
OA10584A (en) 2002-08-26
US6784179B2 (en) 2004-08-31
US6025494A (en) 2000-02-15
US6127542A (en) 2000-10-03
AU689205B2 (en) 1998-03-26
BR9506559A (pt) 1997-10-28
LU91017I2 (fr) 2003-05-26
ZA95424B (en) 1995-09-27
SK94096A3 (en) 1997-04-09
AU1574895A (en) 1995-08-08
EP0740668B1 (fr) 1998-07-29
PL179744B1 (pl) 2000-10-31
US20020119976A1 (en) 2002-08-29
HK1013286A1 (en) 1999-08-20
DE69503753D1 (de) 1998-09-03
RU2142463C1 (ru) 1999-12-10
TW378210B (en) 2000-01-01
DE10399006I1 (de) 2003-07-31
BG100727A (bg) 1997-02-28
ES2122543T3 (es) 1998-12-16
CA2181377A1 (fr) 1995-07-27
AU707055B2 (en) 1999-07-01
CN1224720A (zh) 1999-08-04
JP4347125B2 (ja) 2009-10-21
MX9602904A (es) 1997-12-31
DE69503753T2 (de) 1999-01-21
SV1995000002A (es) 1995-10-04
EE03231B1 (et) 1999-10-15
IL112384A0 (en) 1995-03-30
JP2009102386A (ja) 2009-05-14
JP3808095B2 (ja) 2006-08-09
HU9601982D0 (en) 1996-09-30
GB9401090D0 (en) 1994-03-16
EP0740668A1 (fr) 1996-11-06
NL300124I2 (nl) 2003-11-03
FI113176B (fi) 2004-03-15
FI962927A0 (fi) 1996-07-19
IS4252A (is) 1995-07-22
NO963015D0 (no) 1996-07-19
HRP950023B1 (en) 2000-10-31
LV11690A (lv) 1997-02-20
CZ286566B6 (cs) 2000-05-17
NO2003002I2 (no) 2005-03-21
NO306465B1 (no) 1999-11-08
UY23893A1 (es) 1995-07-11
AP556A (en) 1996-11-07
NL300124I1 (nl) 2003-07-01
PL315559A1 (en) 1996-11-12
AP9500712A0 (en) 1995-01-31
WO1995019978A1 (fr) 1995-07-27
IS1888B (is) 2003-09-01
BR9506559C8 (pt) 2020-07-07
MA23433A1 (fr) 1995-10-01
HU222494B1 (hu) 2003-07-28
CZ211696A3 (en) 1997-06-11
PE49495A1 (es) 1996-01-10
EG25852A (en) 2012-09-10
JPH09508113A (ja) 1997-08-19
SI0740668T1 (en) 1999-02-28
JP2004217674A (ja) 2004-08-05
LV11690B (en) 1997-06-20
NO2003002I1 (no) 2003-01-22
IN183942B (fr) 2000-05-20
IL112384A (en) 1998-08-16
NZ279199A (en) 1998-01-26
US6369059B1 (en) 2002-04-09
RO117794B1 (ro) 2002-07-30
KR100357411B1 (ko) 2003-02-05
SA95150475B1 (ar) 2005-07-31
DK0740668T3 (da) 1999-05-03
AU7391298A (en) 1998-08-20
CN1045777C (zh) 1999-10-20
DE10399006I2 (de) 2004-05-06
CN1143963A (zh) 1997-02-26
SK280879B6 (sk) 2000-08-14
BG62733B1 (bg) 2000-06-30
CO4340684A1 (es) 1996-07-30
FI962927A7 (fi) 1996-07-19
US5859006A (en) 1999-01-12
HRP950023A2 (en) 1998-04-30
CA2181377C (fr) 2002-05-28
CN1070492C (zh) 2001-09-05
SG49184A1 (en) 1998-05-18
HUT74943A (en) 1997-03-28
NO963015L (no) 1996-09-09
MY114663A (en) 2002-12-31

Similar Documents

Publication Publication Date Title
TNSN95004A1 (fr) Derives tetracycliques, procedes de preparation et emploi
EA199800907A1 (ru) Производные карболина
BR9913824A (pt) Combinações de inibidores cìclicos, tetracìclicos de fosfodiesterase especìfica de gmp, com agentes terapêuticos adicionais
CA2134067A1 (fr) Derives de l'adenosine ayant une activite agoniste de l'a2
DK1229040T3 (da) Nukleosid-monophosphatderivater, en fremgangsmåde til fremstilling deraf og anvendelse deraf som immunosuppressive lægemidler
CY1750A (en) Substituted bicycle compounds
TNSN92008A1 (fr) Steroides-esters nouveaux
FR2411179A1 (fr) Nouveaux derives de l'acide 2-(4-thio-2-oxoazetidine-1-yl)-3-methyl-crotonique et procedes pour leur preparation
UA41296C2 (uk) Складні ефіри нуклеозиду та його похідні, фармацевтична композиція на їх основі
FR2434167A1 (fr) Derives de l'hexahydro-1,2,3,3a,8,8a pyrrolo indole (2,3,-b)
NO162421C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenylinderivater og syreaddisjonssalter derav.
FR2395998A1 (fr) Nouveaux derives de la thiazolidine et leur application dans le traitement de l'hypertension
DK243487D0 (da) Heterocyclisk-aromatiske forbindelser, deres fremstilling og farmaceutiske anvendelse
DK316986A (da) Kemiske forbindelser, som er phosphodiesterase type iii inhibitorer
ES8307773A1 (es) "procedimiento para la preparacion de 3-(&-cloropropil)-6-fluor-1,2-bencisoxazol".
MD980248A (ro) Derivaţi ai carbolinei